✓ Translated by DotMD AI Clinical Council Source: Clinical lymphoma, myeloma & leukemia • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #41986167 ↗

Phase III Randomized Trial: Patient Perspective on Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classic Hodgkin Lymphoma Treated With Multiagent Chemotherapy Regimens in the HD21 Trial

Original Paper Title: “Patient Perspective on Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classic Hodgkin Lymphoma Treated With Multiagent Chemotherapy Regimens in the HD21 Trial”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
Systematic Review
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Sensory symptoms, the most frequent CIPN symptoms, tended to be reported by fewer participants in the BrECADD arm than the eBEACOPP arm, while their occurrence followed a similar pattern over time across arms: they were reported during the treatment period, before gradually decreasing post-treatment.
  • Study Design & Sample: Phase III Randomized Trial published in Clinical lymphoma, myeloma & leukemia (Multi-cohort synthesis).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Clinical lymphoma, myeloma & leukemia (2026), this phase iii randomized trial evaluating human clinical outcomes investigated: Patient-reported outcome (PRO) data were analyzed to explore the experience of chemotherapy-induced peripheral neuropathy (CIPN) symptoms by patients with newly-diagnosed advanced-stage classic Hodgkin lymphoma (AS-cHL) treated with BrECADD versus eBEACOPP, and explore the association of CIPN symptoms with health-related quality of life (HRQoL). Key clinical takeaway: Sensory symptoms, the most frequent CIPN symptoms, tended to be reported by fewer participants in the BrECADD arm than the eBEACOPP arm, while their occurrence...

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Clinical lymphoma, myeloma & leukemia, 2026-06-15; Phase III Randomized Trial; Rigor 82/100): Sensory symptoms, the most frequent CIPN symptoms, tended to be reported by fewer participants in the BrECADD arm than the eBEACOPP arm, while their occurrence followed a similar pattern over time across arms: they were reported during the treatment period, before gradually decreasing post-treatment.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: quality-choice-effervescent-cold-relief-plus-aspirin-chlorpheniramine → Rx: quality-choice-pain-relief-powder-aspirin-and-caffeine → Condition: hodgkin-lymphoma → Condition: lymphoma →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 41986167: Phase III Randomized Trial: Patient Perspective on Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classic Hodgkin Lymphoma Treated With Multiagent Chemotherapy Regimens in the HD21 Trial

3 of 3 Free Questions Remaining